Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2012, Vol. 17 ›› Issue (7): 816-820.

Previous Articles     Next Articles

Clinical observation of nebulized budesonide and oral montelukast in the treatment of cough variant asthma

JIA Li-hong ,YAN Juan-juan   

  1. Medical Department of Pediatric, Hangzhou Sixth People's Hospital, Hangzhou Children's Hospital, Hangzhou 310014,Zhejiang,China
  • Received:2012-02-03 Revised:2012-04-06 Published:2012-07-17

Abstract: AIM: To compare the therapy effect of inhalation of budesonide suspension with oral montelukast in cough variant asthma ( CVA ) of children.. METHODS: 118 cases of CVA were divided into group A(n=40) , who were used air compression pump inhalation of budesonide suspension; group B(n=40), who were taken orally montelukast; group C(n=38), who were given loratadine by oral administration .Each group of children were done observation diary every day, recorded the cough,asthma and medication from day to night, followed up once a week in the treatment of 4 weeks,followed up 1-2 times once month after symptom controlled, telephone followed up during the period.If appeared asthma, outpatient was received follow-up. During the follow-up period, three groups were recorded respectively cough symptoms in day and night after treatment with 1, 2, 3, 4, 8, 12 week and done total scores.After 6 months of treatment, we assessed the control condition of asthma. Continue to follow-up 18 months, we observed the recurrence of patients within 2 years and the numbers of wheezing episode and changed into typical asthma (CA) of three groups within 2 years, and recorded the adverse reaction during the treatment. RESULTS: The valid control rates of three groups were 97.5%, 95%, 18.4%, respectively. Compared with group C, the efficacy had significant difference in group A,group B (χ2=16.004, P<0.05). There was no significant difference between group A and group B (χ2=1.946, P>0.05). Compared with before treatment,the total scores was decreased in the treatment of 1, 2, 3, 4 week in group A, group B; In the treatment of 2, 3 week, cough score of group A was decreased obviously than that in group B, the difference was statistically significant (P<0.05); Three groups after treatment, the number of CVA recurrence and wheezing in group A,B was less than that in group C , and relapse rate of group A was 7.5%, wheezing ratio was 10%, while in group B were 25%, 35% (χ2=8.467, P<0.05). CONCLUSION: Compare with take orally montelukast, compress aerosol inhalation budesonide can anesis clinical symptoms better and faster, reduce the recurrence of CVA, effective prevent into typical asthma, and the long-term efficacy is superior to oral montelukast.

Key words: Children, Cough variant asthma, Budesonide, Montelukast

CLC Number: